BioSpace News Archive

Cancer is among the leading causes of death in many countries and is progressively becoming a bigger burden on societies.

For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential for future complications could help stave off severe damage and even a transplant.

Carta Healthcare, provider of solutions for common healthcare data challenges through a combination of people, processes, and artificial intelligence (AI)–powered technology, today announced that it is now a National Cardiovascular Data Registry (NCDR®) certified software vendor for the American College of Cardiology’s (ACC) AFib Ablation Registry™.

AA Pharma Inc. is recalling two lots of Elavil and Apotex Inc. is recalling one additional lot of APO-Amitriptyline 10 mg tablets due to the presence of NDMA, a nitrosamine impurity, above the acceptable limit.

Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.”

Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure, today announced its activities at the upcoming, first ever Technology and Heart Failure Therapeutics conference (THT 2022), which is produced by the Cardiovascular Research Foundation (CRF) and will be held February 1-2 at the New York Marriott Marquis.

South Carolina’s Integrated Micro-Chromatography Systems, Inc. (IMCS), a leader in recombinant enzymes and micro-chromatography technologies, was awarded $1.8 million for Phase II of its Fast-Track Small Business Innovation Research (SBIR) grant from the National Institutes of Health/ National Institute of General Medical Sciences (NIH/NIGMS).

ACCUMTM is an enabling technology as it can be used to enhance the intracellular accumulation of various proteins of pharmacological interests into any target cells.

Polaris Pharmaceuticals, Inc. Vacaville has purchased 15 acres in the City of Vacaville’s Vaca Valley Business Park, a transaction that represents another advancement in the City’s plans to expand its biotechnology footprint and solidify itself as a global center for biomanufacturing.

Establishing cGMP supply for IND-enabling and up to Phase 2 clinical studies for PD-001 oral formulation for esophageal cancer and mild to moderate COVID-19.